# Junta clínica — PT-pseudo_47d8b39fd07f (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_47d8b39fd07f",
  "pid": "PT-pseudo_47d8b39fd07f",
  "task": 1,
  "psa": 21.0,
  "age": 60,
  "months": 1,
  "pirads": "3",
  "psad": 0.19,
  "psav": 5.99,
  "psap": 23.5,
  "vol": 112.15,
  "dre": "Normal",
  "bx": "Negative",
  "cspca": 0.4009605,
  "medhx": "Hypertension, COPD",
  "meds": "amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN",
  "notes": "PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.",
  "pmhx": [
    "Hypertension",
    "COPD"
  ],
  "allergies": [],
  "vitals": {
    "weight": "78 kg",
    "height": "186 cm",
    "bmi": "22.5",
    "bp": "140/82 mmHg",
    "hr": "74 bpm",
    "smoking": "Non-smoker",
    "last_dental": "3 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "22 Jan 2025",
  "enc_ref": "Dr. R. van den Berg (GP)",
  "enc_type": "Re-evaluation - prior negative biopsy",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy."
    },
    {
      "s": "History",
      "t": "The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position."
    },
    {
      "s": "Physical examination",
      "t": "DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected."
    }
  ],
  "occupation": "retired baker",
  "marital": "Married",
  "living": "Lives with adult child (multi-generational household)",
  "next_of_kin": "Adult son (primary contact)",
  "recent_other": [
    "GP practice nurse — flu vaccination",
    "Physiotherapy — lower back, six sessions",
    "Radiology — chest X-ray (routine)"
  ],
  "alcohol": "7 units / week",
  "exercise": "Cycling 5x/week (commuter)",
  "ipss": "IPSS score: 17/35 (moderate LUTS)",
  "admin": "Patient declined research participation previously; respect for AS-related trials.",
  "mri_hospital": "LUMC (Leiden)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_47d8b39fd07f
Task: 1

Encounter: Urology - outpatient on 22 Jan 2025.
Referrer: Dr. R. van den Berg (GP).
Type: Re-evaluation - prior negative biopsy.

Clinical data (read-only — values loaded from the record):
  - 60-year-old male
  - PSA: 21.0 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.19 ng/mL²
  - PSA velocity: 5.99 ng/mL/yr
  - Prior PSA: 23.5 ng/mL
  - Prostate volume: 112.15 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Negative (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.4009605 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, COPD
  - Problem list / PMHx: Hypertension, COPD
  - Current medication: amlodipine, valsartan, lisinopril, metoprolol, tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 21 ng/mL. PI-RADS 3. PSAD 0.19. Prostate volume 112 mL. csPCa 0.40.

Vitals: weight 78 kg, height 186 cm, BMI 22.5, BP 140/82 mmHg, HR 74 bpm. Smoking: Non-smoker.

Chief complaint: Rising PSA trajectory combined with intermediate mpMRI findings warrants specialist review following a previously Negative biopsy.

History: The patient, a 60-year-old retired baker, initially presented for evaluation of PSA elevation in early 2022, with values climbing to 23.5 ng/mL before stabilizing at 21.0 ng/mL. He reports moderate lower urinary tract symptoms, chiefly nocturia and a weak stream, yielding an IPSS score of 17. A Non-smoker, his past medical history encompasses well-controlled hypertension and mild COPD, currently managed with amlodipine, valsartan, lisinopril, metoprolol, tiotropium, and salbutamol PRN. He maintains an active lifestyle, cycling to work five days weekly, and drinks roughly seven units of alcohol each week. Married, he resides in a multi-generational household with his wife and adult son, a setup he describes as highly supportive. Beyond urinary complaints, he notes stable right knee osteoarthritis that required six physiotherapy sessions last year, alongside occasional mild insomnia. He explicitly denies bone pain, haematuria, or unexplained weight loss. He has previously declined research study participation and wishes to maintain that position.

Physical examination: DRE: Normal exam. Prostate texture is symmetrically enlarged, smooth, and firm, lacking discrete nodules or asymmetry. General assessment remains unremarkable, recording blood pressure at 140/82 mmHg and heart rate at 74 bpm, with no peripheral lymphadenopathy or abdominal masses detected.

Patient info: retired baker; Married; Lives with adult child (multi-generational household).
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 7 units / week; exercise Cycling 5x/week (commuter); IPSS score: 17/35 (moderate LUTS).

Recent other appointments: GP practice nurse — flu vaccination; Physiotherapy — lower back, six sessions; Radiology — chest X-ray (routine).
Admin: Patient declined research participation previously; respect for AS-related trials.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.12 (95% CI 0.23-0.71); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior negative biopsy. My criterion answers DEFER.

The criterion: repeat, targeted, when the mpMRI shows a PI-RADS 4-5 lesion; do not repeat a negative biopsy for an unchanged PI-RADS 3 or lower picture. In the labelled series this criterion matched the reading urologist in 16 of 18 cases in exactly this situation.

Like the classifier, I have read ONLY the visible panel — not the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory panel. Departing from me needs a specific
finding from a document somebody actually opened, named out loud. Not a restatement of the
panel numbers I already used.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a PI-RADS threshold of $\ge 3$ is used to trigger a biopsy. It also notes that a PI-RADS threshold of $\ge 3$ would have avoided 30% of all biopsy procedures while missing 11% of detected ISUP GG $\ge 2$ cancers in biopsy-naïve patients.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not sufficiently informed by the guideline because it does not account for the specific risk stratification variables the guideline uses. Specifically, the guideline sets a threshold for PI-RADS ($\ge 3$) which the classifier's bid does not explicitly weigh against the patient's PI-RADS 3 finding. Furthermore, the guideline discusses the trade-off between avoiding biopsies and missing cancer, a nuance that the classifier's simple probability calculation cannot capture.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose shows a PI-RADS score of 3. The guideline makes the decision based on the PI-RADS score threshold, which is the variable that determines the recommendation.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the PI-RADS 3 finding, in the context of a prior negative biopsy, warrants a repeat biopsy according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> To establish the mpMRI prose detailing the PI-RADS 3 finding.
  psa_trend (get_psa_trend) -> What shape does the serial PSA have — rising, flat, falling or oscillating — and over what period?

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What is the mpMRI prose regarding the lesion size, zone, and extraprostatic extension?
  Q2. Does the PSA trend or velocity provide information that modifies the decision regarding the PI-RADS 3 finding?

On the plan itself: 'search_guidelines' is not a document that exists in this task; dropped. psa_trend was added to the plan: the reading urologist opened it in 87% of the labelled cases, and it carries a fact this decision turns on.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose regarding the lesion size, zone, and extraprostatic extension is: "T2 sequences show a 12 mm focus in the right mid-gland peripheral zone, showing intermediate signal with subtly indistinct borders. DWI indicates moderate restriction alongside moderately lowered ADC values. DCE highlights focal early enhancement. Seminal vesicles appear normal. Pelvic lymph nodes show no suspicious features. Extracapsular extension is absent."
psa_trend
The shape of the serial PSA is rising, with values moving from 2.5 ng/mL in Mar 2022 to 21.0 ng/mL in Jan 2025.

WHAT I DID NOT OPEN
I did not open the previous_notes because the moderator did not ask for it, and the information retrieved from the other documents was sufficient to address the open questions.

WHAT THIS SUPPORTS
FOR sampling this patient now
The mpMRI prose identifies a PI-RADS 3 lesion in the right mid-gland peripheral zone.
The PSA trend shows a rising trajectory over the period from Mar 2022 to Jan 2025.
AGAINST sampling this patient now
The prior biopsy was negative.

WHERE THIS LEANS
The PI-RADS 3 finding, combined with a rising PSA trend, suggests that a repeat biopsy is warranted to further characterize the lesion.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened, the `radiology_report` and `psa_trend`, answered the moderator's questions regarding the mpMRI prose and the PSA trend, respectively.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence supports the leaning towards biopsy, which is contrary to the Expert-Classifier's suggestion of "NO BIOPSY". Specifically, the `radiology_report` confirms a PI-RADS 3 lesion, and the `psa_trend` shows a rising trajectory, which aligns with the Registrar's conclusion that a repeat biopsy is warranted.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the mpMRI prose regarding the lesion size, zone, and extraprostatic extension? This is answered by the `radiology_report`, which states: "T2 sequences show a 12 mm focus in the right mid-gland peripheral zone, showing intermediate signal with subtly indistinct borders. DWI indicates moderate restriction alongside moderately lowered ADC values. DCE highlights focal early enhancement. Seminal vesicles appear normal. Pelvic lymph nodes show no suspicious features. Extracapsular extension is absent."
Q2. Does the PSA trend or velocity provide information that modifies the decision regarding the PI-RADS 3 finding? This is answered by the `psa_trend`, which shows a rising trajectory with values moving from 2.5 ng/mL in Mar 2022 to 21.0 ng/mL in Jan 2025.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the PI-RADS score and the PSA trend. The PI-RADS score matters because the EAU guideline uses this threshold to trigger a biopsy decision. The PSA trend matters because it indicates a rising trajectory, which supports the Registrar's finding that a repeat biopsy is warranted. The guideline does not support the classifier's suggestion because it fails to weigh the PI-RADS 3 finding against the guideline's threshold.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a repeat biopsy to further characterize the PI-RADS 3 lesion, given the rising PSA trend. This should be done firmly.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

Given the prior negative biopsy, the PI-RADS 3 finding, and the rising PSA trend from 2.5 to 21.0 ng/mL, a repeat biopsy is warranted to further characterize the lesion. The PI-RADS score is decisive in this context, and the rising PSA trajectory provides additional evidence supporting further sampling. The room converged on proceeding with a repeat biopsy to gain diagnostic certainty.

What carried weight: bx=decisive, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=decisive, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend
